Skip to main content

Table 2 Antimicrotubule trials: survival outcomes.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial Treatment arms Overall survival Progression-free survival or TTP
   N Median (mo) Statistical comparison N Median (mo) Statistical comparison
Tannock, 2004 [64] docetaxel q 3 wks prednisone 335 18.9 HR = 0.76 (95% CI, 0.62–0.94), p = 0.009 NR
  docetaxel q wk prednisone 334 17.4 HR = 0.91 (95% CI, 0.75–1.11) p = 0.36    
  Mitoxantrone prednisone 337 16.5 NA    
Petrylak, 2004 [63] Docectaxel EMP 338 17.5 HR = 0.80 (95% CI, 0.67–0.97) p = 0.02 324 6.3 HR = 0.73 (95% CI, 0.63–0.86) p < 0.001 (TPP)
  Mitoxantrone prednisone 336 15.6   324 3.2  
Abratt, 2004 [62] Vinorelbine hydrocortisone ± AGM 206 14.7 p = 0.95 206 3.7 HR = 0.71 p = 0.055 (unadjusted) p = 0.005 (adjusted)*
  hydrocortisone ± AGM 208 15.2   208 2.8  
Berry, 2001 [84] paclitaxel EMP 166 15.1 p = 0.11 166 NR p = 0.08
  Paclitaxel   12.9     
Hudes, 1999 [61] vinblastine EMP 95 11.9 p = 0.08 98 3.7 p < 0.0004† (TTP)
  Vinblastine 98 9.2   95 2.2  
Iversen, 1997 [65] EMP 61 9.4 p = 0.09 60 2.2  
  Placebo 68 6.1   67 5.0  
Johansson, 1991 [66] EMP 51 NR p = 0.23 51 NR p = 0.28
  MPA 51    51   
De Kernion, 1988 [67] EMP 102 NR p = NS 102 NR p = NS
  Flutamide 101    101   
Murphy, 1979 [68] EMP prednimustine 54 9.3 p = NS NR
  prednimustine 62 9.0     
  1. *Adjusted for age, baseline hemoglobin, performance status, and alkaline phosphatase, and number of prior hormonal manipulations; †based on one-sided significance testing.
  2. Abbreviations: AGM – aminoglutethimide; CI – confidence interval; EMP – estramustine phosphate; HR – hazard ratio; mo – months; MPA – medroxyprogesterone acetate; N – number; NA – not applicable; NR – not reported; NS – non-significant; q – every; TTP – time-to-progression; wk(s) – week(s).